Menu
Search
|

Menu

Close
X

Celcuity Inc CELC.OQ (NASDAQ Stock Exchange Capital Market)

23.48 USD
+0.05 (+0.21%)
As of Jul 21
chart
Previous Close 23.43
Open 23.25
Volume 9,775
3m Avg Volume 9,898
Today’s High 23.90
Today’s Low 22.86
52 Week High 29.19
52 Week Low 11.10
Shares Outstanding (mil) 9.72
Market Capitalization (mil) 126.97
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.195
FY17
-0.759
FY16
-0.395
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
28.24
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

16305 36th Ave N Ste 450
MINNEAPOLIS   MN   55446-4280

Phone: +1763.3920767

Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.

SPONSORED STORIES